Adrenocortical carcinoma laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 6: Line 6:
==Laboratory Findings==
==Laboratory Findings==
Laboratory findings that may associate adrenocortical carcinoma are:
Laboratory findings that may associate adrenocortical carcinoma are:
* {| class="wikitable" ! ! |- | |adrenal androgens [DHEAS], androstenedione,  bioavailable testosterone should be measured in every patient.  17-hydroxyprogesterone  serum estradiol in men and postmenopausal women [85]. |- | |fasting blood glucose,  serum potassium,  cortisol,  ACTH (10 pg/mL)  24-hour urinary free cortisol,  fasting serum cortisol at 8 AM following a 1 mg dose of dexamethasone at bedtime,  |- |exclusion of a pheochromocytoma |metanephrine and normetanephrine in plasma or 24-hour urine and mainly serves to prevent unexpected complications during surgery or treatment (96) |}
Adrenal androgens [DHEAS], androstenedione,  bioavailable testosterone should be measured in every patient.  17-hydroxyprogesterone  serum estradiol in men and postmenopausal women [85].  
fasting blood glucose,  serum potassium,  cortisol,  ACTH (10 pg/mL)  24-hour urinary free cortisol,  fasting serum cortisol at 8 AM following a 1 mg dose of dexamethasone at bedtime,   
exclusion of a pheochromocytoma |metanephrine and normetanephrine in plasma or 24-hour urine and mainly serves to prevent unexpected complications during surgery or treatment (96)


* A recent study has shown significant differences in steroid hormone precursor and metabolite profiles in urine of patients with ACC compared with patients with
* A recent study has shown significant differences in steroid hormone precursor and metabolite profiles in urine of patients with ACC compared with patients with

Revision as of 17:16, 18 September 2017

Adrenocortical carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

CT

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Primary prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma laboratory findings On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenocortical carcinoma laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma laboratory findings

CDC on Adrenocortical carcinoma laboratory findings

Adrenocortical carcinoma laboratory findings in the news

Blogs on Adrenocortical carcinoma laboratory findings

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

Some patients with adrenocortical carcinoma may have elevated concentration of serum cortisol, aldosterone, testosterone or estrogen and reduced concentration of plasma renin and potassium.

Laboratory Findings

Laboratory findings that may associate adrenocortical carcinoma are: Adrenal androgens [DHEAS], androstenedione, bioavailable testosterone should be measured in every patient. 17-hydroxyprogesterone serum estradiol in men and postmenopausal women [85]. fasting blood glucose, serum potassium, cortisol, ACTH (10 pg/mL) 24-hour urinary free cortisol, fasting serum cortisol at 8 AM following a 1 mg dose of dexamethasone at bedtime, exclusion of a pheochromocytoma |metanephrine and normetanephrine in plasma or 24-hour urine and mainly serves to prevent unexpected complications during surgery or treatment (96)

  • A recent study has shown significant differences in steroid hormone precursor and metabolite profiles in urine of patients with ACC compared with patients with

benign adrenal tumors (95). This study defined the 11-deoxycortisol metabolite tetrahydro-11-deoxycortisol as the most discriminative marker, although the overall profile of several metabolites provided more information.

Low serum aldosterone concentrations, normal or high serum or urinary concentrations of aldosterone precursors [86,87]

References

Template:WH Template:WS